NCT04855695 2026-01-21Avo In R/R And Previously Untreated MCLDana-Farber Cancer InstitutePhase 1/2 Recruiting72 enrolled
NCT07052695 2025-12-15Mosunetuzumab for CLL MRD ClearanceDana-Farber Cancer InstitutePhase 1/2 Recruiting40 enrolled